Several breast cancer risk assessment tools have been developed that combine known major risk factors. Risk models can be useful in stratifying patients into risk categories to facilitate personalized screening and surveillance plans for clinical management of the patient.
1. To Identify Women Who May Benefit from Risk-Reducing Medications
The Gail model is used to determine risk for purposes of advising on use of medications to reduce risk. In the National Surgical Adjuvant Breast and Bowel Project (NSABP) P1  study, women at increased risk for breast cancer were defined as follows: 1) age 35 to 59 years with at least a 1.66% five-year risk for developing breast cancer by the Gail model; or 2) personal history of lobular carcinoma in situ (LCIS); or 3) age over 60 years. 13,388 such women were randomized to receive tamoxifen or placebo daily for five years. Tamoxifen reduced the risk of invasive breast cancer by 49% and reduced the risk of noninvasive cancer by 50%.
The reduced risk of breast cancer was only seen for estrogen-receptor expressing tumors. There was a 2.5-fold increase in risk of endometrial cancer in women taking tamoxifen and a decrease in hip and spine fracture risk. Blood clots causing stroke and deep vein thrombosis are increased in women taking tamoxifen [2, 3].
2. To Identify Women Who May Carry a Pathogenic Mutation in BRCA1 or BRCA2
Some models (e.g. Tyrer-Cuzick [IBIS], Penn II, BOADICEA, BRCAPRO) will also calculate the probability of a BRCA1/2 mutation; however, most testing guidelines are now criterion based (e.g. NCCN) as opposed to probability based. In practical terms, clinical decision-making around genetic testing is rarely based on a priori probabilities.
3. To Identify Women Who Meet Criteria for High-Risk Screening MRI
Current American Cancer Society guidelines  recommend annual screening MRI, in addition to mammography, beginning by age 25 to 30 in women who have a lifetime risk (LTR) of breast cancer of 20 to 25% or more. Any of the models used to predict risk of a pathogenic mutation (Tyrer-Cuzick [IBIS], Penn II, BOADICEA, BRCAPRO), or the Claus model, but NOT the Gail model, can be used to estimate lifetime risk for purposes of screening MRI guidelines.
National Comprehensive Cancer Network (NCCN) guidelines also recommend annual screening MRI beginning by age 25, with the addition of mammography beginning at age 30, in women who are known to carry pathogenic mutations in BRCA1 or BRCA2 (unless the woman has had bilateral mastectomy), and in women who are first-degree relatives of known mutation carriers but who are themselves untested (see table below) .
Women who are known to carry or are first-degree untested relatives of individuals with less common disease-causing mutations (such as those associated with Li-Fraumeni syndrome, Bannayan-Riley-Ruvalcaba syndrome, hereditary diffuse gastric cancer, Peutz-Jeghers syndrome, Cowden syndrome, Neurofibromatosis type 1, or Fanconi anemia) are also recommended for annual screening MRI beginning between ages 20-35, depending on the mutation (see table below). Women with known pathogenic mutations in ATM, CHEK2, or NBN should consider annual MRI starting at age 40 or 5-10 years before the earliest known breast cancer in the family (whichever comes first).
Finally, women with prior chest radiation therapy (such as for Hodgkin disease) between ages 10 and 30 are at high risk for developing breast cancer [4, 6, 7], similar in risk to BRCA1 or BRCA2 carriers, and are also recommended for annual screening MRI starting at age 25 or 8 years after the chest radiation therapy, whichever is later.
Table: NCCN Breast Cancer Screening Guidelines in Women Who Carry or Are First-Degree Untested Relatives of Individuals with Pathogenic Mutations Known to Increase Breast Cancer Risk 
|Gene||Associated Hereditary Cancer Syndromes||NCCN Breast Cancer Screening Guidelines|
||Starting age for MRI
|Starting age for
||BRCA-related breast and/or
ovarian cancer syndrome
||BRCA-related breast and/or
ovarian cancer syndrome
||Hereditary diffuse gastric cancer
||Neurofibromatosis type 1
hamartoma tumor syndrome,
and Robin Seitzman, PhD
aScreening recommendations only apply to individuals with a clinical diagnosis of Neurofibromatosis type 1 (NF1).
bThere are currently no data to suggest an increased breast cancer risk after age 50 years in women with NF1; therefore, MRI screening may discontinue at 50 years of age in this group. In addition, the presence of breast neurofibromas may lead to false-positive MRI results; however, more data on sensitivity and specificity of MRI in women with NF1 is needed.
cStart at stated age or 5-10 years before the earliest known breast cancer in the family (whichever comes first).
1. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90:1371-1388
2. Hernandez RK, Sorensen HT, Pedersen L, Jacobsen J, Lash TL. Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study. Cancer 2009; 115:4442-4449
3. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005; 97:1652-1662>
4. Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007; 57:75-89
5. National Comprehensive Cancer Network. Genetic/familial high-risk assessment: Breast, ovarian, and pancreatic, Version 1.2020. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf Published December 4, 2019. Accessed April 25, 2020.
6. Oeffinger KC, Ford JS, Moskowitz CS, et al. Breast cancer surveillance practices among women previously treated with chest radiation for a childhood cancer. JAMA 2009; 301:404-414
7. Monticciolo DL, Newell MS, Moy L, Niell B, Monsees B, Sickles EA. Breast cancer screening in women at higher-than-average risk: Recommendations from the ACR. J Am Coll Radiol 2018; 15:408-414
Table 1 features details and live links to several commonly utilized breast cancer risk assessment models.
Models that do include breast density in risk calculations:
- Tyrer-Cuzick Model (IBIS) version 8 update was based in part on input from Dr. Jennifer Harvey and Dr. Martin Yaffe and includes breast density (Windows/PC only). In this model, breast density is one of the top five factors determining breast cancer risk. This model is the most comprehensive and tends to be the most accurate at predicting risk at the population level.
- Breast Cancer Surveillance Consortium (BCSC) model  is a modification of the Gail model and was developed and validated in a large, ethnically diverse, prospective cohort of women undergoing screening mammography. It includes the risk factors with the greatest population attributable risks for breast cancer, including age, breast density, family history, history of a breast biopsy, and a polygenic risk score (PRS) based on common genetic variations .
- Artificial Intelligence (AI) is being used to identify textural and other findings beyond breast density on mammograms that predict increased risk; such information is complementary to the Tyrer-Cuzick model (v.8) . In a dataset from the Karolinska Institutet, use of AI to identify mammographic microcalcifications and masses, even if not the site of actual malignancy, improved short-term (2-to-3-year) risk assessment over Tyrer-Cuzick (v.7) or Gail models . Such approaches may help determine which women require more frequent or supplemental screening within the next two years.
Models that do not include breast density in risk calculations
1. Tice JA, Cummings SR, Smith-Bindman R, Ichikawa L, Barlow WE, Kerlikowske K. Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med 2008; 148:337-347
2. Vachon CM, Pankratz VS, Scott CG, et al. The contributions of breast density and common genetic variation to breast cancer risk. J Natl Cancer Inst 2015; 107
3. Yala A, Lehman C, Schuster T, Portnoi T, Barzilay R. A deep learning mammography-based model for improved breast cancer risk prediction. Radiology 2019:182716
4. Eriksson M, Czene K, Pawitan Y, Leifland K, Darabi H, Hall P. A clinical model for identifying the short-term risk of breast cancer. Breast Cancer Res 2017; 19:29
5. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989; 81:1879-1886
6. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 1994; 73:643-651
Risk Models and Diagnostic Considerations:
- Risk models may not include known risk factors (e.g. personal history of breast cancer, detailed family history or breast density)
- Estimated absolute risk can vary substantially between models
- Age: As a woman gets older, her 5- and 10-year risk of developing breast cancer increases but her lifetime risk decreases
- Known risks can change every year (particularly as age is a risk factor). Family history may also change as family members may have been diagnosed with breast or ovarian cancer in the interim
Risk Model Limitations:
- Adoption (or otherwise unknown family history)
- Small family size
- All models underestimate rates of breast cancer. At best they predict about 67% of women who will develop cancer at the population level.
- All models are low in accuracy at the individual level ("discrimination")
Indications for Genetic Testing Include :
- Male breast cancer or family history of male breast cancer: 6% of men with breast cancer are found to have a pathogenic mutation in BRCA2
- Personal history of breast cancer and ≤ age 45 at dx; diagnosis at any age and close blood relativea diagnosed ≤ age 50 with breast cancer or close relativea diagnosed with ovarian cancer, pancreatic cancer or metastatic prostate cancer at any age; triple negative breast cancer diagnosed ≤ age 60
aClose blood relatives include first-, second-, and third-degree relatives on the same side of the family.
- First-degree relatives: parents, siblings, and children;
- Second-degree relatives: grandparents, aunts, uncles, nieces, nephews, grandchildren, and half-siblings;
- Third-degree relatives: great-grandparents, great-aunts, great-uncles, great-grandchildren, first cousins, and half aunts and uncles.
- Consider tamoxifen or raloxifene in post-menopausal women with at least one of the following:
- At least 1.67% 5-year risk by Gail model
- Personal history of lobular carcinoma in situ
- Age at least 60 years
- For women with disease-causing BRCA mutation(s), consider bilateral prophylactic mastectomy, risk-reducing salpingo-oophorectomy if at least 10-year life expectancy
Risk Model Indications for Increased Surveillance:
- Supplemental MRI screening beginning by age 25 in “high-risk” women:
- Lifetime risk (LTR) estimated at 20-25% or more by models that predict mutation carrier status
- Disease-causing mutation(s), such as TP53, BRCA, STK11, PTEN or first-degree untested relative of disease-causing mutation carrier but untested
- Prior chest radiation therapy (e.g. for Hodgkin’s disease) before age 30 and at least 8 years earlier
- Continue annual MRI screening (and mammography) to age 70 (unless bilateral mastectomy) if at least 10-year life expectancy, patient continues to meet high-risk guidelines, and can tolerate MRI (no kidney failure, pacemaker, some other metallic implants, severe claustrophobia).
- Supplemental ultrasound screening in women at “high risk” who cannot tolerate MRI, and consider in women with dense breasts, especially if other risk factors (personal history of breast cancer, prior atypical biopsy, intermediate family history).
1. National Comprehensive Cancer Network. Genetic/familial high-risk assessment: Breast, ovarian, and pancreatic, Version 1.2020. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf Published December 4, 2019. Accessed April 25, 2020.